STADA launched Hukyndra a citrate-free, high-concentration (100 mg/mL) biosimilar to adalimumab across immunology, oncology & ophthalmology to patients & caregivers in selected EU countries incl. France, Germany, Finland & Sweden while in further EU countries in coming mos.
The Humira biosimilar consist 40mg/0.4 mL custom-designed pre-filled auto-injector pens, 40mg/0.4 mL & 80mg/0.8 mL pre-filled syringe presentations with 100mg/mL adalimumab. STADA supports Hukyndra’s launch in national markets with educational materials & patient care programs
Adalimumab marks 1st biosimilar developed in collaboration with Alvotech. Hukyndra biosimilar received approval in the EU & was valid in the 27 EU member countries, Norway, Iceland & Liechtenstein
Ref: Businesswire | Image: Alvotech
